An upper intake level of 2 g/day was set to avoid diarrhea and gastrointestinal disturbances with high supplemental intakes
Primary evidence is supplemented by authoritative sources including FDA.gov, NIH.gov, MayoClinic.org, and ClevelandClinic.org due to limited recent peer-reviewed publications on this specific query
Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia
The Most Effective GLP-1/GIP Weight Loss Therapies: A Complete Guide to Tirzepatide and Beyond Last updated: April 2026 If youve been researching weight loss solutions online, youve probably encountered terms like GLP-1, tirzepatide, and semaglutide